Liver and Intrahepatic Bile Duct Carcinoma
NCI Definition: A carcinoma that arises from the hepatocytes or intrahepatic bile ducts. The main subtypes are hepatocellular carcinoma (hepatoma) and cholangiocarcinoma. 
Liver and intrahepatic bile duct carcinomas most frequently harbor alterations in TP53, ARID1A, IDH1, CTNNB1, and BAP1 .
TP53 Mutation, TP53 c.217-c.1178 Missense, TP53 Missense, IDH1 Mutation, and IDH1 Codon 132 Missense are the most common alterations in liver and intrahepatic bile duct carcinoma .
There are 3 clinical trials for liver and intrahepatic bile duct carcinoma, of which 3 are open and 0 are completed or closed. Of the trials that contain liver and intrahepatic bile duct carcinoma as an inclusion criterion, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (1 open).
Bms-986218, cdx-1140, and chemotherapy are the most common interventions in liver and intrahepatic bile duct carcinoma clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.